Norges Bank
RNTX

Norges Bank’s Rein Therapeutics RNTX Stock Holding History

Norges Bank’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-882
Closed -$96K – 2172
2018
Q2 		$96K Sell
882
-1,235
-58% -$140K ﹤0.01% 2116
2018
Q1 		$344K Sell
2,117
-383
-15% -$68.3K ﹤0.01% 2102
2017
Q4 		$527K Hold
2,500
– – ﹤0.01% 2089
2017
Q3 		$669K Hold
2,500
– – ﹤0.01% 2088
2017
Q2 		$558K Buy
+2,500
New +$549K ﹤0.01% 2080

Other funds holding RNTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Norges Bank's RNTX Position: Q3 2018 in Review

Norges Bank sold out of Rein Therapeutics (RNTX) in Q3 2018, closing a stake of 882 shares — an estimated $96K sold.

Norges Bank first reported a position in RNTX in Q2 2017 and held it in 5 quarters. The position peaked at $669K in Q3 2017. 23 funds tracked by Wall St. Rank hold RNTX as of Q3 2018.

  • Norges Bank reported no remaining Rein Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Norges Bank sold 882 Rein Therapeutics shares in Q3 2018, an estimated $96K.
  • Norges Bank first reported a position in Rein Therapeutics in Q2 2017 and held it in 5 quarters.
  • Norges Bank's Rein Therapeutics position peaked at $669K in Q3 2017.
  • 23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2018.

Based on Norges Bank's 13F filing for Q3 2018, filed 9 Nov 2018.